These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

372 related articles for article (PubMed ID: 8773364)

  • 21. L-carnitine treatment of anemia.
    Golper TA; Goral S; Becker BN; Langman CB
    Am J Kidney Dis; 2003 Apr; 41(4 Suppl 4):S27-34. PubMed ID: 12751051
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The management of anemia in pediatric peritoneal dialysis patients. Guidelines by an ad hoc European committee.
    Schröder CH;
    Pediatr Nephrol; 2003 Aug; 18(8):805-9. PubMed ID: 12750985
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Excessive level of parathyroid hormone may induce the reduction of recombinant human erythropoietin effect on renal anemia.
    Fujita Y; Inoue S; Horiguchi S; Kuki A
    Miner Electrolyte Metab; 1995; 21(1-3):50-4. PubMed ID: 7565462
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Recombinant human erythropoietin: 18 months of continuous use in substitution hemodialysis].
    Canaud B; Polito-Bouloux C; Rivory JP; Donnadieu P; Taib J; Florence P; Mion C
    Nephrologie; 1990; 11(1):5-10. PubMed ID: 2374643
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Haemoglobin concentrations in chronic kidney disease.
    Steinbrook R
    Lancet; 2006 Dec; 368(9554):2191-3. PubMed ID: 17189015
    [No Abstract]   [Full Text] [Related]  

  • 26. Anemia and erythropoietin treatment in chronic kidney diseases.
    Santoro A; Canova C
    Minerva Urol Nefrol; 2005 Mar; 57(1):23-31. PubMed ID: 15944519
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Anemia and cardiovascular complications: iron and EPO impact.
    Kurtzman NA; Sabatini S
    Miner Electrolyte Metab; 1999; 25(1-2):109-13. PubMed ID: 10207271
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Correction of anemia by recombinant human erythropoietin in a patient with polycythemia vera associated with hemodialysis-dependent chronic renal failure.
    Ohyashiki JH; Fujieda H; Ohyashiki K; Toyama K
    Am J Hematol; 1991 Jun; 37(2):141-2. PubMed ID: 2069164
    [No Abstract]   [Full Text] [Related]  

  • 29. Effect on hemoglobin F synthesis by erythropoietin in patients with anemia of end-stage renal disease maintained by chronic hemodialysis.
    Salvati F; Strippoli P; Barchetti M; Scatizzi A
    Nephron; 1992; 60(3):371. PubMed ID: 1373475
    [No Abstract]   [Full Text] [Related]  

  • 30. Erythropoietin-resistant refractory renal anemia: effects of oral L-carnitine supplementation.
    Kawabata M; Kasuga S; Hara H; Suyama S; Moriyama K; Takabatake T
    Clin Nephrol; 2001 Mar; 55(3):265-6. PubMed ID: 11316253
    [No Abstract]   [Full Text] [Related]  

  • 31. Effects of L-carnitine supplementation on renal anemia in poor responders to erythropoietin.
    Matsumoto Y; Amano I; Hirose S; Tsuruta Y; Hara S; Murata M; Imai T
    Blood Purif; 2001; 19(1):24-32. PubMed ID: 11114574
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Benefits and concerns of treating pre-dialysis and renal transplant patients with recombinant human erythropoietin.
    Vanrenterghem Y; Vanwalleghem J
    Nephrol Dial Transplant; 1998; 13 Suppl 2():13-5. PubMed ID: 9566485
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The anemia of chronic renal failure: pathophysiology and effects of recombinant erythropoietin.
    Eschbach JW; Haley NR; Adamson JW
    Contrib Nephrol; 1990; 78():24-36; discussion 37. PubMed ID: 2225841
    [No Abstract]   [Full Text] [Related]  

  • 34. The modality of dialysis treatment: does it influence the response to erythropoietin treatment?
    Locatelli F; Del Vecchio L; Andrulli S
    Nephrol Dial Transplant; 2001 Oct; 16(10):1971-4. PubMed ID: 11572880
    [No Abstract]   [Full Text] [Related]  

  • 35. Nutritional implications of recombinant human erythropoietin therapy in renal disease.
    Sanders HN; Rabb HA; Bittle P; Ramirez G
    J Am Diet Assoc; 1994 Sep; 94(9):1023-9. PubMed ID: 8071484
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Role of blood rheology in the pathogenesis of hypertension of hemodialysis patients treated for renal anemia with recombinant human erythropoietin.
    Baldamus CA; Steffen AM; Brunner R; Pollok M
    Contrib Nephrol; 1990; 82():79-85. PubMed ID: 2093531
    [No Abstract]   [Full Text] [Related]  

  • 37. Erythropoietin. A new frontier.
    Rutherford C
    J Intraven Nurs; 1991; 14(3):163-5. PubMed ID: 2033478
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The use of recombinant human erythropoietin (EPO) to correct the anemia of end-stage renal disease: a progress report.
    Adamson W; Egrie JC; Browne JK; Downing MR; Eschbach W
    Behring Inst Mitt; 1988 Aug; (83):188-92. PubMed ID: 3071336
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of angiotensin-converting enzyme inhibitors on anemia in hemodialyzed patients.
    Teruel JL; Fernandez Juarez G; Marcen R; Nogueira J; Ortuño J
    Nephron; 1996; 73(1):113. PubMed ID: 8742977
    [No Abstract]   [Full Text] [Related]  

  • 40. Treatment of renal anemia with recombinant human erythropoietin.
    Schaefer RM; Hörl WH; Massry SG
    Am J Nephrol; 1989; 9(5):353-62. PubMed ID: 2679093
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.